Geode Capital Management LLC Has $51.12 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Geode Capital Management LLC grew its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,988,681 shares of the company's stock after acquiring an additional 43,226 shares during the period. Geode Capital Management LLC owned 2.30% of IDEAYA Biosciences worth $51,121,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of IDYA. Vanguard Group Inc. raised its position in IDEAYA Biosciences by 5.9% in the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock worth $130,507,000 after purchasing an additional 282,936 shares during the last quarter. State Street Corp raised its position in shares of IDEAYA Biosciences by 15.4% during the third quarter. State Street Corp now owns 3,317,936 shares of the company's stock worth $105,112,000 after acquiring an additional 443,640 shares during the last quarter. Pictet Asset Management Holding SA lifted its stake in shares of IDEAYA Biosciences by 2.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,941,271 shares of the company's stock valued at $49,891,000 after acquiring an additional 46,931 shares during the period. Candriam S.C.A. lifted its stake in shares of IDEAYA Biosciences by 14.0% during the fourth quarter. Candriam S.C.A. now owns 1,071,825 shares of the company's stock valued at $27,546,000 after acquiring an additional 131,385 shares during the period. Finally, Fisher Asset Management LLC boosted its holdings in IDEAYA Biosciences by 3.3% in the fourth quarter. Fisher Asset Management LLC now owns 876,599 shares of the company's stock valued at $22,529,000 after acquiring an additional 27,690 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Stock Up 5.6 %

IDEAYA Biosciences stock traded up $0.90 during mid-day trading on Friday, hitting $17.08. 1,657,841 shares of the company's stock were exchanged, compared to its average volume of 940,348. The company's 50 day simple moving average is $18.32 and its 200-day simple moving average is $23.95. The firm has a market capitalization of $1.50 billion, a P/E ratio of -5.18 and a beta of 0.51. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The firm had revenue of $7.00 million during the quarter, compared to the consensus estimate of $7.00 million. Research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Ratings Changes

IDYA has been the topic of a number of research reports. Royal Bank of Canada restated an "outperform" rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Stephens restated an "overweight" rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, IDEAYA Biosciences presently has an average rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.